Efficacy of Tenapanor in Patients With IBS-C: A Post Hoc Analysis of Patients With and Without Prior Use of Other IBS-C Prescription Medications From the Phase 3 T3MPO 1 and T3MPO-2 Studies.
出版信息
Gastroenterol Hepatol (N Y). 2024 Jul;20(7 Suppl 4):2-3.
Abstract
摘要
相似文献
1
Efficacy of Tenapanor in Patients With IBS-C: A Post Hoc Analysis of Patients With and Without Prior Use of Other IBS-C Prescription Medications From the Phase 3 T3MPO 1 and T3MPO-2 Studies.替那诺尔治疗便秘型肠易激综合征患者的疗效：来自3期T3MPO 1和T3MPO - 2研究中曾使用和未使用过其他便秘型肠易激综合征处方药物患者的事后分析
Gastroenterol Hepatol (N Y). 2024 Jul;20(7 Suppl 4):2-3.
2
Comparing the Efficacy of Tenapanor in IBS-C in Hispanic Versus Non-Hispanic Patients: A Post Hoc Analysis of Patients in the Phase 3 T3MPO-1 and T3MPO-2 Studies.比较替那帕诺在西班牙裔与非西班牙裔肠易激综合征便秘型患者中的疗效：3期T3MPO-1和T3MPO-2研究患者的事后分析
Gastroenterol Hepatol (N Y). 2024 Jul;20(7 Suppl 4):4-5.
3
Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study.T3MPO-3 研究中便秘型肠易激综合征患者使用特利加压素的长期安全性。
Neurogastroenterol Motil. 2023 Nov;35(11):e14658. doi: 10.1111/nmo.14658. Epub 2023 Sep 5.
4
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1).治疗便秘型肠易激综合征患者的有效性：一项为期 12 周、安慰剂对照的 3 期试验（T3MPO-1）。
Am J Gastroenterol. 2020 Feb;115(2):281-293. doi: 10.14309/ajg.0000000000000516.
5
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2).Tenapanor 治疗便秘型肠易激综合征患者的疗效：一项 26 周、安慰剂对照的 3 期试验（T3MPO-2）。
Am J Gastroenterol. 2021 Jun 1;116(6):1294-1303. doi: 10.14309/ajg.0000000000001056.
6
Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis.替那诺尔治疗便秘型肠易激综合征患者临床试验期间的腹部症状改善：一项事后分析
Am J Gastroenterol. 2024 May 1;119(5):937-945. doi: 10.14309/ajg.0000000000002685. Epub 2024 Jan 31.
7
Tenapanor: First Approval.特立帕肽：首次批准。
Drugs. 2019 Nov;79(17):1897-1903. doi: 10.1007/s40265-019-01215-9.
8
Tenapanor in the Treatment of Irritable Bowel Syndrome with Constipation: Discovery, Efficacy, and Role in Management.替那帕诺治疗便秘型肠易激综合征：发现、疗效及管理中的作用
Clin Exp Gastroenterol. 2023 Jun 7;16:79-85. doi: 10.2147/CEG.S384251. eCollection 2023.
9
Tenapanor for constipation-predominant irritable bowel syndrome.替那帕诺用于以便秘为主的肠易激综合征。
Drugs Today (Barc). 2020 Mar;56(3):203-210. doi: 10.1358/dot.2020.56.3.3115214.
10
Long-term safety of tenapanor in people with irritable bowel syndrome with constipation from the T3MPO-3 study: plain language summary of publication.T3MPO-3研究中替那诺尔治疗便秘型肠易激综合征患者的长期安全性：出版物的通俗易懂总结
Therap Adv Gastroenterol. 2024 Apr 9;17:17562848241237196. doi: 10.1177/17562848241237196. eCollection 2024.
本文引用的文献
1
An Overview of the Effects of Tenapanor on Visceral Hypersensitivity in the Treatment of Irritable Bowel Syndrome with Constipation.替那诺尔治疗便秘型肠易激综合征对内脏高敏感性影响的概述
Clin Exp Gastroenterol. 2024 Apr 10;17:87-96. doi: 10.2147/CEG.S454526. eCollection 2024.
2
Tenapanor in the Treatment of Irritable Bowel Syndrome with Constipation: Discovery, Efficacy, and Role in Management.替那帕诺治疗便秘型肠易激综合征：发现、疗效及管理中的作用
Clin Exp Gastroenterol. 2023 Jun 7;16:79-85. doi: 10.2147/CEG.S384251. eCollection 2023.
3
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2).Tenapanor 治疗便秘型肠易激综合征患者的疗效：一项 26 周、安慰剂对照的 3 期试验（T3MPO-2）。
Am J Gastroenterol. 2021 Jun 1;116(6):1294-1303. doi: 10.14309/ajg.0000000000001056.
4
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1).治疗便秘型肠易激综合征患者的有效性：一项为期 12 周、安慰剂对照的 3 期试验（T3MPO-1）。
Am J Gastroenterol. 2020 Feb;115(2):281-293. doi: 10.14309/ajg.0000000000000516.
Zotero 插件